Radiopharm Theranostics Ltd
No enriched coverage for $RADX in the last 7 days.
No SEC Form 4 filings for $RADX in the last 30 days.
See all $RADX insider activity →Radiopharm Theranostics (RADX) announced its Phase 1 HEAT trial for 177Lu-RAD202 will advance to Cohort 4 at a higher 180mCi dose level, per the Data Safety and Monitoring Committee's recommendation. The trial, evaluating RAD202 for HER2-positive advanced solid tumors, previously used a 130mCi dose. RADX stock closed at $2.50, up 1.20% in pre-market trading.
Radiopharm Theranostics (RADX) said it will hold an End-of-Phase 2 meeting with the FDA on Oct. 1, 2026 to align on pivotal Phase 3 trial design for RAD101 in suspected recurrent brain metastases after radiotherapy. The company cited Phase 2b results showing 93% MRI concordance and selective tumor uptake. RAD101 has Fast Track status and Siemens will manufacture and distribute it for a planned Phase 3 starting Q4 2026.
Radiopharm Theranostics (NASDAQ: RADX) entered a securities purchase agreement for a registered direct offering of 1,281,646 ADSs (384,493,800 ordinary shares) at $3.16 per ADS, raising about $4.1 million gross. Investors also receive unregistered warrants for up to 1,281,646 ADSs, exercisable after shareholder approval at $3.79 per ADS, expiring July 31, 2029. Closing expected around July 28, 2026.
Recent RADX coverage spans technology, corporate actions and regulation.
The dose escalation suggests positive safety data and may boost investor confidence in RADX's lead radiotherapeutic candidate.
FDA alignment on pivotal Phase 3 design is a near-term regulatory milestone that can de-risk trial execution and timelines for RAD101.
The company is issuing new equity via ADS, which can pressure near-term valuation via dilution and financing overhang.
Dilutive capital raise with warrant overhang likely drives near-term selling pressure and raises dilution risk.
Clinical readouts improve perceived probability of future regulatory discussions for RAD101 and dose selection for a planned Phase 2 trial of RAD204.
alphai scores every news story that mentions RADX with an AI model for sentiment and relevance, and aggregates insider trades from Radiopharm Theranostics Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Radiopharm Theranostics (RADX) announced its Phase 1 HEAT trial for 177Lu-RAD202 will advance to Cohort 4 at a higher 180mCi dose level, per the Data Safety and Monitoring Committee's recommendation. The trial, evaluating RAD202 for HER2-positive advanced solid tumors, previously used a 130mCi dose. RADX stock closed at $2.50, up 1.20% in pre-market trading.
1 min readRadiopharm Theranostics (RADX) said it will hold an End-of-Phase 2 meeting with the FDA on Oct. 1, 2026 to align on pivotal Phase 3 trial design for RAD101 in suspected recurrent brain metastases after radiotherapy. The company cited Phase 2b results showing 93% MRI concordance and selective tumor uptake. RAD101 has Fast Track status and Siemens will manufacture and distribute it for a planned Phase 3 starting Q4 2026.
3 min readRadiopharm Theranostics (NASDAQ: RADX) entered a securities purchase agreement for a registered direct offering of 1,281,646 ADSs (384,493,800 ordinary shares) at $3.16 per ADS, raising about $4.1 million gross. Investors also receive unregistered warrants for up to 1,281,646 ADSs, exercisable after shareholder approval at $3.79 per ADS, expiring July 31, 2029. Closing expected around July 28, 2026.
2 min readRadiopharm Theranostics (NASDAQ: RADX) shares fell about 21% after the company announced a $13 million capital raise via concurrent U.S. and Australian offerings. It will issue 1,281,646 ADS at $3.16 in a registered direct offering, raising about $4.1 million gross. It also plans warrants at $3.79 per ADS, expiring July 31, 2029, subject to shareholder approval.
4 min readRadiopharm Theranostics (RADX) reported positive clinical updates. In a Phase 2b trial, RAD101 met its primary endpoint, showing 86% accuracy for detecting brain metastases across tumor types, with specificity due in Q4 2026. In a Phase 1 trial, RAD204 showed a RECIST-confirmed durable partial response at 90 mCi, with no dose-limiting toxicities. RADX stock last $4.29.
4 min readDSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025
2 min read
